Clover Health Investments Corp. (CLOV) Records 4.90% Price increase in Monday Trading

The closing price of Clover Health Investments Corp. (NASDAQ: CLOV) was $1.07 for the day, up 4.90% from the previous closing price of $1.02. In other words, the price has increased by $+0.0500 from its previous closing price. On the day, 5088922 shares were traded. CLOV stock price reached its highest trading level at $1.0750 during the session, while it also had its lowest trading level at $1.0000.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.



Our analysis of CLOV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.10. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 470.59M and an Enterprise Value of 59.76M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.17 while its Price-to-Book (P/B) ratio in mrq is 1.60. Its current Enterprise Value per Revenue stands at 0.02 whereas that against EBITDA is -0.18.

Stock Price History:

Over the past 52 weeks, CLOV has reached a high of $3.55, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is 0.8658, while the 200-Day Moving Average is calculated to be 1.4304.

Shares Statistics:

CLOV traded an average of 6.70M shares per day over the past three months and 7.93M shares per day over the past ten days. A total of 478.81M shares are outstanding, with a floating share count of 346.34M. Insiders hold about 3.10% of the company’s shares, while institutions hold 32.50% stake in the company. Shares short for CLOV as of Apr 27, 2023 were 39.82M with a Short Ratio of 39.82M, compared to 32.32M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.28% and a Short% of Float of 10.14%.

Earnings Estimates

The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.19, while EPS last year was -$0.22. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.09 and low estimates of -$0.16.

Analysts are recommending an EPS of between -$0.42 and -$0.7 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.4, with 5 analysts recommending between -$0.16 and -$0.61.

Revenue Estimates

It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $515.78M to a low estimate of $474.22M. As of the current estimate, Clover Health Investments Corp.’s year-ago sales were $846.7M, an estimated decrease of -42.00% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $488.83M, a decrease of -42.90% less than the figure of -$42.00% in the same quarter last year. There is a high estimate of $505.6M for the next quarter, whereas the lowest estimate is $477.2M.

A total of 6 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $2.05B, while the lowest revenue estimate was $1.97B, resulting in an average revenue estimate of $2B. In the same quarter a year ago, actual revenue was $3.48B, down -42.50% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $2.11B in the next fiscal year. The high estimate is $2.22B and the low estimate is $1.99B. The average revenue growth estimate for next year is up 5.50% from the average revenue estimate for this year.